WallStSmart

West Pharmaceutical Services Inc (WST)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 14760% more annual revenue ($3.07B vs $20.69M). WST leads profitability with a 16.1% profit margin vs 5.8%. WST trades at a lower P/E of 36.1x. WST earns a higher WallStSmart Score of 55/100 (C-).

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91

ZJYL

Avoid

27

out of 100

Grade: F

Growth: 2.7Profit: 4.5Value: 3.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued
ZJYLSignificantly Overvalued (-127.0%)

Margin of Safety

-127.0%

Fair Value

$0.07

Current Price

$1.94

$1.87 premium

UndervaluedFair: $0.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

ZJYL1 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Areas to Watch

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

ZJYL4 concerns · Avg: 2.8/10
Market CapQuality
$303.70M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.8%3/10

ROE of 4.8% — below average capital efficiency

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
194.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bull Case : ZJYL

The strongest argument for ZJYL centers on Price/Book.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Bear Case : ZJYL

The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin. A P/E of 194.0x leaves little room for execution misses.

Key Dynamics to Monitor

WST profiles as a mature stock while ZJYL is a value play — different risk/reward profiles.

ZJYL carries more volatility with a beta of 9.47 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

WST scores higher overall (55/100 vs 27/100), backed by strong 16.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.

Want to dig deeper into these stocks?